Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.58 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21650578 | 0.86 | HDAC6 (0.44) | HDAC6SLC27A1MAOBNPC1HTT | |
| SCHEMBL23571162 | 0.85 | HDAC6 (0.64) | HDAC6SLC27A1MAOB | |
| SCHEMBL21634089 | 0.82 | HDAC6 (0.70) | HDAC6HDAC1 | |
| SCHEMBL21634130 | 0.78 | HDAC6 (0.61) | HDAC6SMN1; SMN2 | |
| SCHEMBL21634094 | 0.77 | HDAC6 (0.62) | HDAC6NPC1RAB9A | |
| SCHEMBL21634115 | 0.77 | HDAC6 (0.64) | HDAC6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21634292 | 0.76 | HDAC6 (0.71) | HDAC6HDAC1 | |
| SCHEMBL21634103 | 0.75 | HDAC6 (0.70) | HDAC6HDAC1 | |
| SCHEMBL23571109 | 0.74 | HDAC6 (0.69) | HDAC6NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL23571110 | 0.74 | HDAC6 (0.61) | HDAC6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958844-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-04-16 | — | — | US | disclosed |
| EP-3827004-B1 | 4-(1,3,4-OXADIAZOLE-2-YL)PYRIDINE-2(1H)-ONE DERIVATIVES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS FOR THE TREATMENT OF E.G. INFECTIONS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-10-11 | — | — | EP | disclosed |
| US-20210188831-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-06-24 | — | — | US | disclosed |
| EP-3827004-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020022794-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958844-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885SLC27A1 2018/4885MAOB 509/4885 |
| US-20210188831-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885SLC27A1 2018/4885MAOB 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.